19 patents
Utility
Toll-like receptor antagonist compounds and methods of use
28 Nov 23
Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
Filed: 20 May 22
Utility
Coronavirus Vaccines Comprising a TLR9 Agonist
13 Jul 23
The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif.
John D. CAMPBELL, Robert S. JANSSEN, David NOVACK
Filed: 1 Mar 21
Utility
CpG-adjuvanted SARS-CoV-2 virus vaccine
27 Jun 23
Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
Filed: 10 Sep 21
Utility
Coronavirus Vaccines Comprising a TLR9 Agonist
13 Apr 23
The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif.
John D. CAMPBELL, Robert S. JANSSEN, David NOVACK, Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun LIN, Yu-Chi WU
Filed: 1 Mar 21
Utility
Coronavirus Vaccines Comprising a TLR9 Agonist
23 Mar 23
The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif.
John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
Filed: 1 Mar 21
Utility
Active Booster Immunization Against Tetanus, Diphtheria and Pertussis
9 Mar 23
The present disclosure relates to immunogenic compositions comprising tetanus, diphtheria, and acellular pertussis (Tdap) antigens, and a toll-like receptor 9 (TLR9) agonist, such as oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif.
John D. CAMPBELL, Robert L. COFFMAN, Randall N. HYER, Robert S. JANSSEN, David NOVACK, Martin GOHLKE, Maureen URBAN, Sunil GAIROLA, Umesh SHALLIGRAM, Manish GAUTUM, Harish RAO
Filed: 9 Mar 21
Utility
Shingles Vaccines Comprising a TLR9 Agonist
2 Mar 23
The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif.
John D. CAMPBELL, Randall N. HYER, Robert S. JANSSEN, David NOVACK
Filed: 9 Mar 21
Utility
CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
9 Feb 23
Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
Filed: 10 Sep 21
Utility
Toll-like Receptor Antagonist Compounds and Methods of Use
22 Sep 22
Albert Frederick CANDIA, Richard Thomas BERESIS, Robert L. COFFMAN
Filed: 20 May 22
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
3 Feb 22
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Stewart D. CHIPMAN, Radwan KIWAN, Melissa A. KACHURA, Robert COFFMAN
Filed: 16 Aug 21
Utility
IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
7 Oct 21
The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun Lin, Yu-Chi WU, John Darren CAMPBELL, Robert S. JANSSEN, David NOVACK
Filed: 18 Jun 21
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
21 Sep 21
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Stewart D. Chipman, Radwan Kiwan, Melissa A. Kachura, Robert Coffman
Filed: 2 Mar 20
Utility
Combination of a PD-1 Antagonist and CPG-C Type Oligonucleotide for Treating Cancer
1 Jul 21
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
Filed: 21 Aug 20
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
24 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
Filed: 25 May 16
Utility
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
27 Jul 20
The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker.
Robert L. Coffman, Stewart D. Chipman, Radwan Kiwan, Samuel Zalipsky, Gary S. Ott
Filed: 12 Nov 18
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
24 Jun 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Stewart D. CHIPMAN, John DEMATTEI, Radwan KIWAN, Melissa A. KACHURA
Filed: 1 Mar 20
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
13 Apr 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Stewart D. Chipman, John Demattei, Radwan Kiwan, Melissa A. Kachura
Filed: 20 Aug 18
Utility
Branched chimeric compounds, and methods of use thereof
3 Feb 20
The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides.
Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan Kiwan, Holger Kanzler
Filed: 19 Apr 18
Utility
Toll-like Receptor Antagonist Compounds and Methods of Use
13 Nov 19
Albert Frederick CANDIA, III, Richard Thomas BERESIS, Robert L. COFFMAN
Filed: 8 Nov 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first